Vivos Therapeutics, Inc. - 8-K Filing
Vivos Therapeutics reports Q3 2026 revenue of $6.4 million, a 24% quarter-over-quarter increase, and regained Nasdaq compliance following SOD Sciences transaction. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $VVOS